RxDoctor Payments Data

Debasis Das, MD

Interventional Cardiology · Little Rock, ARNPI 1265467609

Payments from drug & device makers

$1,309in general payments, 2019–2025

Across 51 payments — averaging $25.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$315
  • Boston Scientific$256
  • Novartis$245
  • Abbott$208
  • E.r. Squibb & Sons, L.L.C.$82
  • Irhythm Technologies, Inc.$61
  • plus $143 from 5 others

What the payments were for

  • Food & beverage$1,309100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,309 in reported general payments places this provider in the 10th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$304,983
Medicare patients
1,280
Services billed
3,741

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban528$401,349
EntrestoSacubitril/Valsartan307$283,287
JardianceEmpagliflozin103$86,633
XareltoRivaroxaban101$74,117
FarxigaDapagliflozin Propanediol73$52,811
Repatha SureclickEvolocumab23$12,883
Ranolazine ErRanolazine92$5,504
Atorvastatin Calcium660$5,205
Metoprolol Succinate311$3,567
Isosorbide Dinitrate99$3,239
Carvedilol428$2,811
SotalolSotalol Hcl196$2,541
Diltiazem 24hr ErDiltiazem Hcl77$2,011
Amlodipine Besylate432$1,992
Cilostazol85$1,981

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$245$283,287307 claims
Boehringer IngelheimJardiance$15$86,633103 claims
Johnson & JohnsonXarelto$47$74,117101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 89 interventional cardiology providers in Arkansas.

Other interventional cardiology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →